RxDoctor Payments Data

Kanti Agrawal, MD

Cardiovascular Disease · Garland, TXNPI 1942285671

Payments from drug & device makers

$2,493in general payments, 2019–2025

Across 116 payments — averaging $21.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$559
  • Merck$503
  • Novartis$372
  • E.r. Squibb & Sons, L.L.C.$177
  • Pfizer$148
  • Johnson & Johnson$136
  • plus $597 from 9 others

What the payments were for

  • Speaking & faculty fees$40016%
  • Food & beverage$2,07983%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,493 in reported general payments places this provider in the 40th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$68,580
Medicare patients
240
Services billed
928

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban135$153,238
XareltoRivaroxaban23$17,507
EntrestoSacubitril/Valsartan15$12,829
Repatha SyringeEvolocumab12$11,007
Losartan Potassium282$2,678
Rosuvastatin Calcium162$2,494
Digoxin105$2,411
Metoprolol Succinate194$2,384
Prasugrel Hcl19$2,317
Amlodipine Besylate341$1,751
Valsartan37$1,702
Nebivolol Hcl31$1,533
ClopidogrelClopidogrel Bisulfate122$1,469
Lisinopril147$1,335
Atorvastatin Calcium102$1,128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$148$153,238135 claims
Johnson & JohnsonXarelto$136$17,50723 claims
NovartisEntresto$372$12,82915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Garland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →